# Cellnovo

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cellnovo

- Industry: Medical Devices & Equipment
- Headquarters: Swansea, UK
- Website: www.cellnovo.com
- Total disclosed funding: $48M
- Latest round: Series B (Feb 4, 2011)
- Investors on record: 8

## About

Cellnovo is a pioneering technology company specializing in diabetes management solutions, combining innovative devices with digital health services to empower patients in managing their condition effectively.Cellnovo, founded in 2002 in Swansea, UK, develops advanced diabetes management systems that integrate hardware and software solutions. The company has undergone strategic pivots, notably transitioning to an IPO in July 2015 where it raised EUR 32.4 mn by selling 3.05 million shares at EUR 10.63 each. Julian Shapley, the founder, has a history in technology ventures, further enhancing the company’s expertise. Cellnovo primarily operates out of Swansea and has focused its efforts on enhancing its product offerings in the diabetes care sector.Cellnovo specializes in diabetes management solutions, offering a unique combination of connected insulin delivery devices and comprehensive digital health services. Their core product enables patients to manage their insulin delivery efficiently while tracking their glucose levels, thereby improving health outcomes. The company primarily caters to the European and North American markets, providing essential tools for individual users and healthcare professionals to enhance diabetes management.In 2017, Cellnovo reported a revenue of EUR 1,377,326.10, with an EBITDA of EUR -14,104,267.70, reflecting the company’s ongoing investments in product development and market expansion.Following its IPO on July 9, 2015, Cellnovo plans to leverage the raised EUR 32.4 mn to expedite the development of new diabetes management products and enhance its existing services. The company is targeting expansion into additional European markets and aims to establish a stronger presence in North America by 2025, capitalizing on the rising demand for innovative diabetes solutions. Upcoming product launches are anticipated to bolster their market position and meet the growing needs of diabetic patients.

## Funding rounds

- Series B, Feb 4, 2011, $48M — Auriga Partners, HealthCare Ventures, Andera Partners, Omnes Capital, Stage Capital, Forbion, NESTA Investments, Advent Life Sciences

## Investors

- Auriga Partners (https://capitalatlas.ai/funds/auriga-partners) — Series B
- HealthCare Ventures — Series B
- Andera Partners (https://capitalatlas.ai/funds/andera-partners) — Series B
- Omnes Capital (https://capitalatlas.ai/funds/omnes-capital) — Series B
- Stage Capital (https://capitalatlas.ai/funds/stage-capital) — Series B
- Forbion (https://capitalatlas.ai/funds/forbion) — Series B
- NESTA Investments — Series B
- Advent Life Sciences (https://capitalatlas.ai/funds/advent-life-sciences) — Series B